Document:

Exhibit 10.2

 

FIRST FINANCIAL SERVICE CORPORATION

2012 NON-EMPLOYEE DIRECTOR EQUITY COMPENSATION
PROGRAM

 

Restricted Stock Award Agreement 

 

First Financial Service Corporation ("the
Company") grants as of _________________, 20___ (the "Grant Date") to ______________________________________ (the
"Director" or "you") the number of shares set forth below, of the common stock of the Company under the Company’s
2012 Non-Employee Director Equity Compensation Program ("Program") and its 2006 Stock Option and Incentive Compensation
Plan (“Plan”). Copies of the Program and the Plan are attached, and any capitalized terms used but not defined in this
Agreement shall have the meaning given them in the Program or the Plan, as the case may be.

 

Grant
of Award. Subject to the terms and conditions of this Agreement and the Plan, the Company hereby grants to you a Restricted
Stock Award in the amount of ____ shares of Stock (the "Shares"). These shares will be issued to you after you sign this
Agreement, but are subject to forfeiture if you terminate employment with the Company.

 

Restriction
Period.  The Restricted Stock will vest at the close of business on the day immediately preceding the first anniversary
of the Award Date stated above, provided you continue to serve as a member of the Board as of the date of vesting.  However,
your Restricted Stock will become fully vested if there is a Change in Control of the Company as defined in the Plan.

 

Taxation
of Award. Your Restricted Stock will be taxable when it vests, at the value on the vesting date. See the attachment
to this Agreement explaining your option to include the value of the shares in income within 30 days of the Grant Date. If you
wish to make this election, please check below.

 

£ I elect to make
an 83(b) tax election to include the value of Shares granted to me in income now.

 

Transfer
Restrictions.  Until such time as the Shares become vested as set forth above, the Shares shall not be transferred,
pledged or disposed of except by will or the laws of descent and distribution, and are subject to forfeiture in accordance with
this Agreement, the Program and the Plan.  

 

Acknowledgments.
By signing below, you acknowledge that you have received a copy of the Program and the Plan, and you hereby accept the Shares
subject to all the terms and provisions of the Program and the Plan.

 

	 	 	 	FIRST FINANCIAL SERVICE CORPORATION
	 	 	 	 	 
	 	 	By:	 
	Director	 	 	 	 
	 	 	 	 	 
	Date:	 	 	Date:	 

 

    	 

    	 

    

 

Important Information About Section 83(b) Election to
Include Value of Restricted Stock Grant in Income at Grant Date: 

 

As a recipient of a
restricted stock grant under the First Financial Service Corporation Amended and Restated 2006 Stock Incentive Plan, you may make
an election (called an "83(b) election") to recognize compensation income when the stock is granted, even though the
stock is then subject to a risk of forfeiture (vesting). Making an 83(b) election causes current taxation of the fair market value
of the stock granted, and withholding taxes are immediately due.

 

By making an 83(b)
election, any later appreciation in the stock will be taxed as capital gain income, and your holding period for capital gain purposes
will begin on the date of taxation. An 83(b) election must be made, if at all, within 30 days after the transfer of the stock
to you.

 

The downside of making
an 83(b) election is that the election is generally irrevocable. Also, if you forfeit the stock, you may not receive any deduction
for the amount previously included in income.

 

To the extent an 83(b)
election is not made, the Company will be treated as the owner of the stock that continues to be subject to restriction
for tax purposes, so any dividends will be treated as compensation paid to you by the Company.

 

    	-2-

    	 

    

 

ELECTION TO INCLUDE VALUE 

OF RESTRICTED STOCK AWARD IN GROSS INCOME

PURSUANT TO SECTION
83(b) OF THE INTERNAL REVENUE CODE

 

__________________________ [insert date]

 

The undersigned hereby
elects, under IRC Section 83(b) to include in gross income, as compensation for services, the excess of the fair market value at
the time of transfer of the property described below over the amount paid for such property.

 

The following information
is supplied in accordance with Treasury Regulation §1.83-2(e):

 

1.          The
name, address and social security number of the undersigned:

 

Name: __________________________

 

Address: ________________________________________________

 

________________________________________________________

 

_________________________________________________________

 

SSN: __________________________________

 

2.          The
property with respect to which the election is being made is common stock of First Financial Service Corporation

 

3.          The
property was transferred on _____________________________ [insert date]. The taxable year for which election is made is calendar
year 20____.

 

4.          The
nature of the restrictions or risks of forfeiture to which the property is subject is that if the undersigned ceases to serve as
a director of the Company or its subsidiary, the undersigned's unvested restricted stock will be forfeited. The undersigned vests
in the property at the close of business on the day immediately preceding the first anniversary of the above stated date on which
the property was transferred, or upon a change in control as defined in the Company’s 2006 Stock Option and Incentive Compensation
Plan.

 

5.          The
fair market value of property at the time of transfer (determined without regard to any lapse restriction) was $_____________.

 

6.          The
taxpayer received the property solely for the performance of services.

 

7.          Copies
of this statement have been have been furnished, as required by Reg 1.83-2(d), to First Financial Service Corporation and its subsidiary
for which the services were performed.

 

	 	 
	 	[Signature]

 

    	-3-

    	 

    

 

Instructions for Filing:
File this statement within 30 days from the Grant Date with IRS at the address you will use to file your 1040 for the tax year
involved as stated in item 3 above, AND file it with your tax return for that year.

 

    	-4-September 24, 2012

Robert Jones

Acura Pharmaceuticals, Inc.

616 N. North Court, Suite 120

Palatine, IL 60067

 

		Re:	License, Development and Commercialization Agreement, dated October 30, 2007, by and between Acura
Pharmaceutical, Inc. and King Pharmaceuticals Research and Development, Inc. (the “Agreement”)

 

Dear Robert:

 

The purpose of this
letter agreement is to memorialize the Parties’ (i) termination of the Agreement with respect to certain Products, and (ii)
agreement to amend certain post-termination provisions in the Agreement, all as discussed in our recent communications (this “Letter
Agreement”). All capitalized terms used but not defined herein shall have the meanings set forth in the Agreement.

 

The Parties hereby
acknowledge and agree as follows:

 

		1.	Termination of Certain Products. The Parties acknowledge and agree that, on July 26, 2012,
King provided proper written notice of termination, without cause, of the Agreement with respect to Product B, Product C, and Product
D, and any Product Line Extension of Product B, Product C, and Product D (collectively, the “Returned Products,”
and each individually, a “Returned Product”).

 

		2.	Waiver of Prior Written Notice and Termination Date. With respect to any Returned Product,
Acura further acknowledges and agrees to forever and irrevocably waive the requirement to provide twelve (12) months written notice
to Acura prior to terminating the Agreement with respect to such Returned Product as described in Section 16.3. The effective date
of termination of the Agreement with respect to the Returned Products shall be the date set forth above (the “Letter
Agreement Effective Date”).

 

		3.	Limited Waiver of Non-Compete. Notwithstanding King’s termination and return of the
Returned Products, the Parties acknowledge and agree that the provisions of the covenant not to compete set forth in Section 13.1(a)(i)
and (ii) of the Agreement as of the Letter Agreement Effective Date shall continue to apply, provided however, that the covenant
not to compete in Section 13.1(a)(i) shall not apply to Product B or to any Product Line Extension of Product B, and the covenant
not to compete in Section 13.1(a)(ii) shall not apply to Product C, Product D (or to any Product Line Extension of Product C or
Product D) or to any of the Future Products listed on Schedule A. For avoidance of doubt, Acura and its Affiliates may, directly
or indirectly, Commercialize Product B, Product C, Product D, and/or any of the Future Products listed on Schedule A or any Product
Line Extension of any of the foregoing or grant any right to Third Parties to Commercialize Product B, Product C, Product D, and/or
any of the Future Products listed on Schedule A or any Product Line Extension of any of the foregoing in the Territory. For purposes
of clarity, the covenant not to compete set forth in Section 13.1(b)(i) of the Agreement shall not apply to the Returned Products
or any of the Future Products listed on Schedule A.

 

[***Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been separately filed with
the Commission.]

 

    	 

    	 

    

 

		4.	Future Product Options. The Parties acknowledge and agree to forever and irrevocably waive
any future obligations and rights with respect to the Future Products listed in Schedule A to this Letter Agreement, and
any rights and obligations under Sections 2.1(e), 2.1(f), and 8.6 of the Agreement shall terminate as of the Letter Agreement Effective
Date.

 

		5.	Trademarks. The Parties acknowledge and agree that the definition of Trademarks set forth
in Section 1.86 of the Agreement shall no longer include the marks Acurox or Acuracet. For the avoidance of doubt, Acura shall
have the exclusive right to the Acurox and Acuracet trademarks and to any domain names incorporating or utilizing Acurox or Acuracet.

 

		6.	Transition. In connection with the termination of the Agreement with respect to the Returned
Products, the Parties acknowledge and agree to follow certain activities to support the transition of the Returned Products all
in accordance with Section 16.7(b) of the Agreement, as described in Schedule B to this Letter Agreement (the “Transition
Plan”), which Transition Plan shall constitute Acura’s request under Section 16.7(b). The Parties acknowledge
and agree that the Joint Steering Committee (or a subcommittee thereof) shall facilitate the implementation of the Transition Plan,
provided that the Transition Plan and its implementation may not be amended without the mutual written consent of Acura and King.
King will commence delivering the items specified in the Transition Plan as soon as they become available, but final delivery of
the Transition Plan in no event shall be later than ninety (90) days from the Letter Agreement Effective Date. With respect to
the clinical supplies and samples specified in the Transition Plan, King will deliver to Acura, FOB shipping point, freight collect.

 

		7	Licenses. To facilitate Acura’s continued development of the Returned Products, King
hereby grants to Acura: at no cost (1) a fully paid-up non-exclusive license under King Sole Inventions relating to any Returned
Product or the Aversion technology to develop, manufacture, use, sell offer for sale and import Returned Products inside the Territory
including the right to grant sublicenses and (2) a right to reference and use all regulatory data from Product A inside the Territory
for products listed on Schedule A, Product B, Product C and Product D and any Product Line Extensions of the foregoing.

 

[***Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been separately filed with
the Commission.]

 

    	 

    	 

    

 

		8.	Publicity. Neither party will originate any publicity, press release, or other public announcement
or make any comment, written or oral, relating to this Letter Agreement without the advance written consent of the other Party
(except as has been previously consented), unless such announcement is required by law or the regulations of a national securities
exchange. A Party required by law, rule or regulation or the regulation of a national securities exchange to make such an announcement
will give the other Party an opportunity to review the form or content of such announcement and make comments upon it in advance.
Either Party may issue a press release in the form substantially similar to Schedule C to this Letter Agreement. The Parties
acknowledge that Acura will file a Form 8-K with the Securities and Exchange Commission regarding this Letter Agreement and will
be attaching a redacted copy of the Letter Agreement to such 8-K (or a Form 10-Q or 10-K as appropriate) requesting confidential
treatment of certain information and the 8-K and redacted copy will be treated as a public announcement as described herein.

 

		9.	Confidentiality. The terms of this Letter Agreement and the Schedules attached hereto shall
be deemed Confidential Information of Disclosing Party.

 

Except as explicitly
set forth in this Letter Agreement, no amendment or modification to the Agreement is hereby made.

 

Sincerely,

 

King Pharmaceuticals
Research and Development, Inc.

 

	By:	/s/ Robert B. Lamm	 
	 	 	 
	Name:	Robert B. Lamm	 
	 	 	 
	Title:	Vice President	 

 

Accepted and agreed as of the date first set forth above.

 

ACURA PHARMACEUTICALS, INC.

 

	By:	/s/ Robert B. Jones	 

 

	Name: Robert B. Jones
	 
	Title: President and Chief Executive Officer

 

[***Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been separately filed with
the Commission.]

 

    	 

    	 

    

 

SCHEDULE A

 

List of mu opioids* for which Pfizer forever
and irrevocably waives any future obligations and rights with respect to the Future Products

 

	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

 

* Includes all pharmaceutically acceptable salts thereof.

 

[***Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been separately filed with
the Commission.]

 

    	 

    	 

    

 

SCHEDULE B

 

		1.	Definitions (all including Acura’s Aversion® Technology):

	Product B (oxycodone/APAP/niacin)	Product B-LE (oxycodone/APAP)
	Product C (hydrocodone/APAP/niacin)	Product C-LE (hydrocodone/APAP)

	Product D [***]	Product D-LE [***]

 

* Denotes High Priority Items for early transfer, if possible

 

		2.	Products B, C and D (products with niacin)

[***] 

 

		3.	Product B-LE

 

[***]  

 

Product C-LE [***]  

 

Product D-LE [***]

 

[***Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been separately filed with
the Commission.]

 

    	 

    	 

    

 

SCHEDULE C

 

Form of Release

 

Acura Pharmaceuticals Announces Earlier
Return of Development Products

 

Palatine, IL - (XXXXXXX, YY, 2012) - Acura Pharmaceuticals,
Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products
intended to address medication abuse and
misuse, announced today a letter agreement with Pfizer Inc. providing for the termination of Pfizer’s license to Acura’s
AVERSION Technology used in three developmental opioid products as of [date as inserted in the agreement] and the transfer of those
products back to Acura. On July 26, 2012 Acura was notified by Pfizer of its intention to terminate the license to the three development
products which carried a 12 month notice period under the terms of the companies’ 2007 license agreement.

 

The developmental products being returned to Acura are oxycodone
hydrochloride with acetaminophen, hydrocodone bitartrate with acetaminophen and a third previously unnamed opioid, all of which
utilize Acura’s AVERSION technology. The AVERSION Technology utilizes a proprietary mixture of inactive ingredients to discourage
tampering of a product for abusive purposes.

“We are pleased that Pfizer agreed to an earlier return
of these development products for development by Acura”, said Bob Jones, President and Chief Executive Officer of Acura Pharmaceuticals.

 

[***Confidential treatment requested pursuant to a
request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been separately
filed with the Commission.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]